Ringer’s Injection, USP in VIAFLEX Plastic Container

DESCRIPTION

Ringer’s Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents. The pH may have been adjusted with sodium hydroxide. Composition, osmolarity, pH and ionic concentration are shown in Table 1.

<table>
<thead>
<tr>
<th>Size (mL)</th>
<th>Composition (g/L)</th>
<th>Ionic Concentration (mEq/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sodium Chloride, USP (NaCl)</td>
<td>Sodium</td>
</tr>
<tr>
<td>500</td>
<td>8.6</td>
<td>147.5</td>
</tr>
<tr>
<td>1000</td>
<td>8.6</td>
<td>147.5</td>
</tr>
<tr>
<td></td>
<td>Calcium Chloride, USP (CaCl₂·2H₂O)</td>
<td>Potassium</td>
</tr>
<tr>
<td></td>
<td>0.33</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Potassium Chloride, USP (KCl)</td>
<td>Chloride</td>
</tr>
<tr>
<td></td>
<td>309</td>
<td>4.5</td>
</tr>
<tr>
<td></td>
<td>5.5 (5.0 to 7.5)</td>
<td>156</td>
</tr>
</tbody>
</table>

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

CLINICAL PHARMACOLOGY

Ringer’s Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.
INDICATIONS AND USAGE
Ringer’s Injection, USP is indicated as a source of water and electrolytes.

CONTRAINDICATIONS
Concomitant treatment with ceftriaxone and Ringer’s Injection, USP is contraindicated in newborns (≤28 days of age), even if separate infusion lines are used due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream.

WARNINGS
Ringer’s Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

Ringer’s Injection, USP should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

Ringer’s Injection, USP should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation.

The intravenous administration of Ringer’s Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.

In patients with diminished renal function, administration of Ringer’s Injection, USP may result in sodium or potassium retention.

In patients older than 28 days, including adults, ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Ringer’s Injection, USP, through the same infusion line (e.g., via a Y-connector). If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid.
PRECAUTIONS
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Caution must be exercised in the administration of Ringer’s Injection, USP to patients receiving corticosteroids or corticotropin.

Pregnancy
Teratogenic Effects
Pregnancy Category C
Animal reproduction studies have not been conducted with Ringer’s Injection, USP. It is also not known whether Ringer’s Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ringer’s Injection, USP should be given to a pregnant woman only if clearly needed.

Pediatric Use
The use of Ringer’s Injection, USP in pediatric patients is based on clinical practice.

Geriatric Use
Clinical studies of Ringer’s Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Do not administer unless solution is clear and seal is intact.

**Drug Interactions**
For information on the use of Ringer’s Injection, USP with ceftriaxone, see CONTRAINDICATIONS and WARNINGS sections.

**ADVERSE REACTIONS**
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

**DOSAGE AND ADMINISTRATION**
As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.

Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

**HOW SUPPLIED**
Ringer’s Injection, USP in VIAFLEX plastic container is available as follows:

<table>
<thead>
<tr>
<th>Code</th>
<th>Size (mL)</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2B2303</td>
<td>500</td>
<td>0338-0105-03</td>
</tr>
<tr>
<td>2B2304</td>
<td>1000</td>
<td>0338-0105-04</td>
</tr>
</tbody>
</table>
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.

DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER

To Open
Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.

Preparation for Administration
1. Suspend container from eyelet support.
2. Remove protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication
WARNING: Additives may be incompatible

To add medication before solution administration
1. Prepare medication site.
2. Using syringe with 19 to 22 gauge needle, puncture medication port and inject.
3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration
1. Close clamp on the set.
2. Prepare medication site.
3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.

4. Remove container from IV pole and/or turn to an upright position.

5. Evacuate both ports by squeezing them while container is in the upright position.

6. Mix solution and medication thoroughly.

7. Return container to in use position and continue administration.

**Baxter Healthcare Corporation**
Deerfield, IL 60015 USA

Printed in USA

07-19-73-751

Rev. October 2014

Baxter, Pl 146 and Viaflex are trademarks of Baxter International Inc.